Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis?

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 986-987

  Bicanic, Tihana ^a,b,c   Jarvis, Joseph N ^a,b,c   Muzoora, Conrad ^d   Harrison, Thomas S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c GF Jooste Hospital   (South Africa)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

CRYPTOCOCCAL MENINGITIS; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LETTER; MENTAL FUNCTION; MONOTHERAPY; PRIORITY JOURNAL; SURVIVAL; THERAPY DELAY; TREATMENT PLANNING; ZIMBABWE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; MENINGITIS, CRYPTOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; ZIMBABWE;

EID: 77957851331     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656437     Document Type: Letter

References (12)

1. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis 2010; 50(11):1532-1538.
2. Carter M. Risk of IRIS means that HIV treatment should be delayed for patients taking fluconazole for cryptococcal meningitis. NAM Web site. http://www.aidsmap.com/en/news/3A5FFA0E-CD35-41AE-903C-AFC382975233.asp. Published 10 May 2010. Accessed 10 May 2010.
3. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45(1):76-80.
4. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47(12):1556-1561.
5. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46(11):1694-1701.
6. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010; 50(3):338-344.
7. Bicanic T, Wood R, Meintjes G, et al. High dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV: a randomized study. Clin Infect Dis 2008; 47:123-130.
8. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. South Afr J HIV Med 2007; 28:25-35.
9. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50(3):291-322.
10. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19(10):1043-1049.
11. Shelburne SA III, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40(7):1049-1052. (Pubitemid 40418316)
12. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22(15):1897-1908.